Top

Published in:

01-06-2020 | Editorial and Commentary

Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?

Authors: Roberto Salvia, Giuseppe Malleo, Laura Maggino, Michele Milella, Claudio Bassi

Published in: Updates in Surgery | Issue 2/2020

Excerpt

In his landmark publication “The structure of scientific revolutions” Harvard Philosopher Thomas Kuhn challenged the traditional view of science as the progressive accumulation of knowledge, and affirmed the concept of “progress through revolutions”. In this framework, the reiteration of anomalies within a given conceptual network triggers a crisis whereby the underlying assumptions of the field are reexamined and a new paradigm is established. Maybe for the first time in the management of pancreatic ductal adenocarcinoma (PDAC), we are standing on the edge of such revolutionary shift. …

Groot VP, Gemenetzis G, Blair AB (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269(6):1154–1162. https://doi.org/10.1097/SLA.0000000000002734 CrossRefPubMed

Mackay TM, Smits FJ, Roos D et al (2019) The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. HPB (Oxford). https://doi.org/10.1016/j.hpb.2019.06.019 CrossRef

Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRef

Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17:801–810CrossRef

Crippa S, Cirocchi R, Weiss MJ et al (2020) A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg. https://doi.org/10.1007/s13304-020-00710-z CrossRefPubMed

Jang J-Y, Han Y, Lee H et al (2018) Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 268:215–222CrossRef

Reni M, Balzano G, Zanon S et al (2018) Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol 3:413–423CrossRef

Versteijne E, Suker M, Groothuis K et al (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. https://doi.org/10.1200/JCO.19.02274(Epub ahead of print) CrossRefPubMed

Salvia R, Casciani F, Sereni E, Bassi C (2019) Pancreatic cancer—What’s next? Presse Med 48(3 Pt 2):e187–e197. https://doi.org/10.1016/j.lpm.2019.02.031 CrossRefPubMed

10.

Maggino L, Malleo G, Marchegiani G et al (2019) Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. https://doi.org/10.1001/jamasurg.2019.2277(Epub ahead of print) CrossRefPubMed

11.

NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma. National Comprehensive Cancer Network. 2020 version 1

Title: Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Authors: Roberto Salvia
Giuseppe Malleo
Laura Maggino
Michele Milella
Claudio Bassi
Publication date: 01-06-2020
Publisher: Springer International Publishing
Published in: Updates in Surgery / Issue 2/2020
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI: https://doi.org/10.1007/s13304-020-00798-3

At a glance: The STEP trials

Springer Medicine

Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2020

Postoperative outcomes in patients undergoing colorectal surgery with anastomotic leak before and after hospital discharge

In memory of a great surgeon: Valerio Di Carlo (1938–2020)

Feasibility of enhanced recovery after surgery program in colorectal surgery during COVID-19 pandemic in Italy: should we change something?

Clinical implications of COVID-19 in patients with chronic liver disease and liver tumor

Continuing our work: transplant surgery and surgical oncology in a tertiary referral COVID-19 center

The Italian National Registry for minimally invasive pancreatic surgery: an initiative of the Italian Group of Minimally Invasive Pancreas Surgery (IGoMIPS)